RIGging functional outcomes in glioma cells: new insights into LRIG proteins in malignant gliomas.

摘要

Malignant gliomas are the most aggressive and common forms of brain cancer in adults with a high mortality rate. One type of malignant glioma is Glioblastoma Mutiforme (GBM), W.H.O. grade IV astrocytoma, with a median overall survival (OS) for patients of less than 15 mo. Treatments usually consist of multimo-dality therapy with surgery to establish a diagnosis and debulk the enhancing tumor mass, followed by concurrent chemoradiation and then adjuvant chemotherapy. This approach, accompanied by improvements in radiation delivery to the tumor using 3D conformal treatment planning has improved the 2 y OS to-25% compared to -10% for patients who receive only adjuvant radiation.1 However, most malignant gliomas are generally resistant to treatments and there are few long-term survivors. This resistance to chemotherapy is partially due to genetic alterations in receptor signaling pathways. Recent collaborative studies by Parsons D, et al.